IHS Markit Ltd. (INFO - Free Report) reported strong fourth-quarter fiscal 2019 results, with earnings and revenues beating the Zacks Consensus Estimate.
Adjusted earnings per share of 65 cents beat the consensus mark by 6.6% and increased 14% on a year-over-year basis. Total revenues came in at $1.12 billion, surpassing the consensus mark by 0.05% and improving 5% from the year-ago quarter.
We observe that shares of IHS Markit have gained 57.5% over the past year, outperforming 43.4% growth of the industry it belongs to.
Revenues at the Resources segment totaled $237.6 million, up 7% year over year, with recurring revenues rising 5% organically. The Transportation segment experienced year-over-year revenue growth of 9% to reach $324.5 million. Recurring revenues at this segment grew 12% organically.
Revenues at the CMS segment amounted to $127.7 million, down 8% year over year, with 1% organic growth in recurring revenues. Financial services segment’s revenues increased 5% year over year to $430.6 million, with 8% organic growth in recurring revenues.
Recurring fixed revenues of $810.1 million rose 6% year over year on a reported basis and 7% on an organic basis. Recurring variable revenues of $147.5 million grew 6% year over year on a reported basis and 7% on an organic basis. Non-recurring revenues totaled $162.8 million, down 2% year over year on a reported basis but up 1% on an organic basis.
Adjusted EBITDA of $452.9 million increased 8.6% from the year-ago quarter. Adjusted EBITDA margin improved 130 points (bps) year over year to 40.4%.
IHS Markit ended the quarter with cash and cash equivalent balance of $111.5 million compared with $124.1 million in the prior quarter. Long-term debt was $4.9 billion compared with $5.1 billion in the previous quarter.
Cash flow from operations and free cash flow amounted to $225.7 million and $147.5 million, respectively, in the quarter. CapEx was $78.2 million. The company repurchased $500 million of shares in fiscal 2019.
Fiscal 2020 Outlook
IHS Markit expects revenues of $4.52 billion to $4.59 billion, including organic growth of 5% to 6%. The Zacks Consensus Estimate for revenues is pegged at $4.41 billion. Adjusted EBITDA is expected in the range of $1.86 billion to $1.89 billion. Adjusted EPS of $2.82 to $2.88 is anticipated. The Zacks Consensus Estimate for earnings is pegged at $2.58.
Zacks Rank & Stocks to Consider
IHS Markit currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Business Services sector are S&P Global (SPGI - Free Report) , Accenture (ACN - Free Report) and Booz Allen Hamilton (BAH - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The long-term expected EPS (three to five years) growth rate for S&P Global, Accenture and Booz Allen Hamilton is 10%, 10.3% and 13%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>